Oncologists debate ethics of controlled trials for genetic drugs

09/21/2010 | New York Times (tiered subscription model), The

Controlled trials are considered essential for proving a drug works better than other treatments or placebo. Controlled trials of Roche Holding's melanoma drug PLX4032, however, have added to the debate about whether controlled trials are ethical for evaluating cancer drugs that target genomic mutations. "[With genetically targeted] drugs that have minimal side effects and dramatic response rates, where we understand the biology, I wonder, why do we have to be so rigorous?" asked the chairman of human oncology at Memorial Sloan-Kettering Cancer Center. "This could be one of those defining cases that says, 'Look, our system has to change.'"

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN